[Federal Register Volume 71, Number 131 (Monday, July 10, 2006)]
[Notices]
[Pages 38890-38891]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-10727]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: (N)-Methanocarba 
Adenosine Derivative as A3 Receptor Agonists

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

[[Page 38891]]

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license worldwide to practice the invention embodied in: 
International Patent Application PCT/US2005/031678 filed September 2, 
2005 entitled, ``(N)-Methanocarba Adenosine Derivative as A3 Receptor 
Agonists'', to Can-Fite BioPharma, Ltd. having a place of business in 
Petach-Tikva, Israel. The contemplated exclusive license may be limited 
to an FDA approvable human therapeutic for cancer, autoimmune and other 
inflammatory diseases. The United States of America is the assignee of 
the patent rights in this invention.

DATES: Only written comments and/or application for a license which is 
received by the NIH Office of Technology Transfer on or before 
September 8, 2006 will be considered.

ADDRESSES: Request for a copy of the patent, inquiries, comments, and 
other materials relating to the contemplated license should be directed 
to: Norbert Pontzer, Technology Licensing Specialist, Office of 
Technology Transfer, National Institutes of Health, 6011 Executive 
Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: 301-435-
5502; Facsimile: 301-402-0220; e-mail: [email protected].

SUPPLEMENTARY INFORMATION: Researchers have been pursuing compounds 
that activate or inhibit adenosine A3 receptors because these cell 
membrane proteins have a wide range of physiological and disease-
related effects and are thus considered to be promising drug targets. 
The adenosine A3 receptors are G-protein-coupled receptors and are 
found mostly in brain, lung, liver, heart, kidney, and testis. When 
this receptor is activated moderately, a cytoprotective effect is 
observed, such as reducing damage to heart cells from lack of oxygen. 
However, at high levels of stimulation they can cause cell death. Both 
agonists and antagonists are being tested for therapeutic potential, 
for example, treatment of cancer, heart conditions, neurological 
conditions, pain, asthma, inflammation and other immune implications. 
This invention pertains to highly potent A3 adenosine receptor 
agonists, pharmaceutical compositions comprising such nucleosides, and 
a method of use of these nucleosides.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless, within 60 days 
from the date of this published Notice, the NIH receives written 
evidence and argument that establishes that the grant of the license 
would not be consistent with the requirements of 35 U.S.C. 209 and 37 
CFR 404.7.
    Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: June 29, 2006.
David R. Sadowski,
Acting Director, Division of Technology Development and Transfer, 
Office of Technology Transfer, National Institutes of Health.
[FR Doc. E6-10727 Filed 7-7-06; 8:45 am]
BILLING CODE 4140-01-P